The Activity of Doxorubicin Niosomes Against an Ovarian Cancer Cell Line and Three in Vivo Mouse Tumour Models

References

• Azmin M. N., Florence A. T., Handjani-Vila R. M., Stuart J. F.B., Vanlerberghe G., Whittaker J. S. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J. Pharm. Pharmacol. (1985); 37: 237–242
   PubMed Web of Science ®Google Scholar
• Balazsovits J. A.E., Mayer L. D., Bally M. B., Cullis P. R., McDonnel M., Ginsberg R. S., Falk R. E. Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumour efficacy of doxorubicin. Cancer Chemother. Pharmacol. (1989); 23: 81–86
   PubMed Web of Science ®Google Scholar
• Calabersi P., Chabner B. A. Antineoplastic agents. Goodman and Gilman's Pharmacological Basis of Therapeutics (8th edition), A. Goodman Gilman, T. W. Rail, S. A. Nies, P. Taylor. Pergamon Press, New York (1990); 1209–1263
   Google Scholar
• Cowens J. W., Creaven P. J., Greco W. R., Brenner D. E., Tung Y., Ostro M., Ginsberg R., Petrelli N. Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes). Cancer Res. (1993); 53: 2796–2802
   PubMed Web of Science ®Google Scholar
• Cuvier C., Roblot-Treupel L., Millot J. M., Lizard G., Chevillard S., Manfait M., Couvreur P., Poupon M. F. Doxorubicin-loaded nanospheres bypass tumour cell multidrug resistance. Biochem. Pharmacol. (1992); 44: 509–517
   PubMed Web of Science ®Google Scholar
• Danhauser-Riedl S., Hausmann E., Schick H-D., Bender R., Dietzfelbinger H., Rastetter J., Hanauske A-R. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Investig. New Drugs (1993); 11: 187–195
   PubMed Web of Science ®Google Scholar
• Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs (1992); 3: 175–210
   PubMed Web of Science ®Google Scholar
• Duncan R., Vasey P., Kaye S. B., Cassidy J. Development of PK1, an HPMA copolymer doxorubicin conjugate, the CRC experience Pavlidis N. Proceedings of the EORTC Early. Drug Development Meeting 1995, Corfu, June, 21–241995. Oncology Department, University of Ionnina, Ionnina, 60–61
   Google Scholar
• Florence A. T., Cable C., Cassidy J., Kaye S. B. Non-ionic surfactant vesicles as carriers of doxorubicin. Targeting of Drugs, G. Gregoriadis, A. C. Allison, G. Poste. Plenum Press, New York (1990); 117–126
   Google Scholar
• Gabizon A. A. Selective tumour localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. (1992); 52: 891–896
   PubMed Web of Science ®Google Scholar
• Gabizon A., Dagan A., Goren D., Barenholz Y., Fuks Z. Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumour activity in mice. Cancer Res. (1982); 42: 4734–4739
   PubMed Web of Science ®Google Scholar
• Gabizon A., Catane R., Uziely B., Kaufmann B., Safra T, Cohen R., Martin E, Huang A., Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. (1994); 54: 987–992
   PubMed Web of Science ®Google Scholar
• Haran G., Cohen R., Bar L. K., Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim. Biophys. Acta (1993); 1151: 201–215
   PubMed Web of Science ®Google Scholar
• Harrap K. R., Jones M., Pollard L. A., Kelland L. R. The establishment, characterization and calibration of human ovarian cancer xenografts for the evaluation of novel platinum anticancer drugs. Ann. Oncol. (1990); 1: 65–76
   PubMed Web of Science ®Google Scholar
• Houghton J. A., Houghton P. J. The suitability and use of human tumour xenografts. Rodent Tumour Models in Experimental Cancer Chemotherapy, R. F. Kallman. Pergamon Press, New York (1987); 199–204
   Google Scholar
• Huang S. K., Lee K-D., Hong K., Friend D. S., Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. (1992); 52: 5135–5143
   PubMed Web of Science ®Google Scholar
• Katagari Y., Mabuchi K., Itakura T, Naora K., Iwamoto K., Nozu Y., Hirai S., Ikeda N., Kawai T. Adriamycin-lipiodol suspension for i.a. chemotherapy of hepatocellular carcinoma. Cancer Chemother. Pharmacol (1989); 23: 238–242
   PubMed Web of Science ®Google Scholar
• Kerr D. J., Rogerson A., Morrison G. J., Florence A. T., Kaye S. B. Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft. Br. J. Cancer (1988); 58: 432–436
   PubMed Web of Science ®Google Scholar
• Kwon G., Yokoyama M., Okano T., Sakurai Y., Kataoka K. Enhanced tumour accumulation and prolonged circulation times of micelle forming poly(ethylene oxide-aspartate) block copolymer-adriamycin conjugates. J. Control. Rel (1994); 29: 17–23
   Web of Science ®Google Scholar
• Lin S-Y, Wu W-H., Lui W-Y. In vitro release, pharmacokinetic and tissue distribution studies of doxorubicin hydrochloride (adriamycin HC1) encapsulated in lipiodolized w/o emulsions and w/o/w multiple emulsions. Pharmazie (1992); 47: 439–443
   PubMed Web of Science ®Google Scholar
• Matsumara Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy; mechanism for tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. (1986); 6: 6387–6392
   Google Scholar
• Oudard S., Thierry A., Jorgensen T. J., Rahman A. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother. Pharmacol (1991); 28: 259–265
   PubMed Web of Science ®Google Scholar
• Priebe W., Van N. T., Burke T. G., Perez-Soler R. Removal of the basic centre from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anti-Cancer Drugs (1993); 4: 37–48
   PubMed Web of Science ®Google Scholar
• Rahman A., Husain S. R., Siddiqui J., Verma M., Agresti M., Center M., Safa A. R., Glazer R. I. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J. Natl. Cancer Inst. (1992); 84: 1909–1915
   Google Scholar
• Rogerson A., Cummings J., Willmott N., Florence A. T. The distribution of doxorubicin in mice following administration in niosomes. J. Pharm. Pharmacol. (1988); 40: 337–342
   PubMed Web of Science ®Google Scholar
• Sadasivan R., Morgan R., Fabian C., Stephens R. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin. Cancer Lett. (1991); 57: 165–171
   PubMed Web of Science ®Google Scholar
• Sharp S. Y., Rowlands M. G., Jarman M., Kelland L. R. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines. Br. J. Cancer, 70: 409–414
   PubMed Web of Science ®Google Scholar
• Siemann D. Satisfactory and unsatisfactory tumour models: factors influencing the choice of a tumour model for experimental evaluation. Rodent Tumour Models in Experimental Cancer Chemotherapy, R. F. Kallman. Pergamon Press, New York (1987); 12–15
   Google Scholar
• Sikic B. I. Modulation of multidrug resistance: at the threshold. J. Clin. Oncol. (1993); 111: 1629–1635
   Google Scholar
• Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesh H., Kenney S., Boyd M. R. New colorimetric assay for anticancer-drug screening. J. Natl. Cancer Inst. (1990); 82: 1107–1113
   PubMed Web of Science ®Google Scholar
• Solary E., Bidan J-M., Calvo F., Chauffert B., Calliot D., Mugneret F., Gauville C., Tsuruo T., Carli P-M., Guy H. P-glycoprotein expression and in vitro reversion of doxorubicin resistance by verapamil in clinical specimens from acute leukaemia and myeloma. Leukemia (1991); 5: 592–597
   PubMed Web of Science ®Google Scholar
• Steel G. G. How well do xenografts maintain the therapeutic response characteristics of the source tumour in the donor patient?. Rodent Tumour Models in Experimental Cancer Chemotherapy, R. F. Kallman. Pergamon Press, New York (1987); 205–208
   Google Scholar
• Thierry A. R., Jorgensen T. J., Forst D., Belli J. A., Dritschilo A., Rahman A. Modulation of multidrug resistance in Chinese hamster cells by liposome-encapsulated doxorubicin. Cancer Commun. (1989); 1: 311–316
   PubMedGoogle Scholar
• Thierry A. R., Dritschilo A., Rahman A. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem. Biophys. Res. Commun. (1992); 187: 1098–1105
   PubMed Web of Science ®Google Scholar
• Thierry A. R., Vigé D., Coughlin S. S., Belli J. A., Dritschillo A., Rahman A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J. (1993); 7: 572–579
   PubMed Web of Science ®Google Scholar
• Uchegbu I. F., Turton J. A., Double J. A., Florence A. T. Drug distribution and a pulmonary adverse effect of intraperitoneally administered doxorubicin niosomes in the mouse. Biopharm. Drug Dispos. (1994); 15: 691–707
   PubMed Web of Science ®Google Scholar
• Uchegbu I. F., Double J. A., Turton J. A., Florence A. T. Distribution, metabolism and tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span 60) niosomes in the mouse. Pharm. Res. (1995); 12: 1019–1024
   PubMed Web of Science ®Google Scholar
• Unezaki S., Maruyama K., Ishida O., Takahashi N., Iwatsuru M. Enhanced tumour targeting of doxorubicin by ganglioside GM1-bearing long-circulating liposomes. J. Drug Target. (1993); 1: 287–292
   PubMed Web of Science ®Google Scholar
• Vaage J., Mayhew E., Lasic D., Martin F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int. J. Cancer (1992); 51: 942–948
   PubMed Web of Science ®Google Scholar
• Vanlerberghe G., Handjani-Vila R-M., Berthelot C., Sebag H. (1973) Synthèse et activité de surface comparee d'une série de nouveaux dérivé non ioniques. Proceedings of the 6th International Congress on Surface Active Agents. 1972. Carl Hanser, Munchen, 139–155
   Google Scholar
• Volm M., Mattern J. Detection of multiple resistance mechanisms in untreated human lung cancer. Onkologie (1993); 16: 189–194
   Web of Science ®Google Scholar
• Williams S., Alosco T. R., Mayhew E., Lasic D. D., Martin F. J., Bankert R. B. Arrest of human lung tumour xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res. (1993); 53: 3964–3967
   PubMed Web of Science ®Google Scholar
• Willmott N., Kamel H. M.H., Cummings J., Stuart J. F.B., Florence A. T. Adriamycin-loaded albumin microspheres: lung entrapment and fate in the rat. Microspheres and Drug Therapy. Pharmaceutical, Immunological and Medical Aspects, S. S. Davis, L. Illum, J. G. McVie, E. Tomlinson. Elsevier Science, London (1984); 205–215
   Google Scholar
• Woodcock D. M., Linsenmeyer M. E., Chojnowski G., Kriegler A. B., Nink V, Webster L. K., Sawyer W. H. Reversal of multidrug resistance by surfactants. Br. J. Cancer (1992); 66: 62–68
   PubMed Web of Science ®Google Scholar
• Yeung T. K., Hopewell J. W., Simmonds R. H., Seymour L. W., Duncan R., Bellini O., Grandi M., Spreafico F., Strohalm J., Ulbrich K. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. (1991); 29: 105–111
   PubMed Web of Science ®Google Scholar
• Yokoyama M., Miyauchi M., Yamada N., Okano T., Sakurai Y., Kataoka K., Inoue S. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res. (1990); 50: 1693–1700
   PubMed Web of Science ®Google Scholar
• Zhang Y., Sweet K. M., Sognier M. A., Belli J. A. An enhanced ability for transforming adriamycin into a noncyto-toxic form in a multidrug-resistant cell line (LZ-8). Biochem. Pharmacol. (1992); 44: 1869–1877
   PubMed Web of Science ®Google Scholar